To include your compound in the COVID-19 Resource Center, submit it here.

The roots of rarity

How and why Pfizer rare disease unit is aggregating technologies

Pfizer Inc. is expanding its rare disease development toolkit to include technologies that act upstream of protein expression to treat the root cause of disease, with an emphasis on adeno-associated viral vectors to correct loss-of-function mutations.

Pfizer launched its rare disease research unit in 2010 to coordinate and build on the company's R&D in monogenetic disorders. Because each disease is driven by a single gene defect, but different monogenetic diseases are driven by targets with very different characteristics, unit SVP and CSO Kevin Lee told BioCentury the group has spent the past two years scrutinizing technologies that may be able to correct a disease at a

Read the full 1063 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers